We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-13.46%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.59B
AUM Growth
-$417M
Cap. Flow
-$178M
Cap. Flow %
-6.89%
Top 10 Hldgs %
30.75%
Holding
151
New
30
Increased
31
Reduced
32
Closed
17

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$42M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$38M
3
AAC
AAC Holdings
AAC
+$37.8M
4
GSK icon
GSK
GSK
+$37.7M
5
RGNX icon
Regenxbio
RGNX
+$34.1M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$132M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$38M
3
INGN icon
Inogen
INGN
+$26.8M
4
AERI
Aerie Pharmaceuticals
AERI
+$25.4M
5
BSX icon
Boston Scientific
BSX
+$24.9M

Sector Composition

Rank Sector Weight
1 Healthcare 68.89%
2 Financials 4.77%
3 Technology 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACUR
101
DELISTED
Acura Pharmaceuticals
ACUR
$2.41M 0.09%
+1,025,641
New +$3.49M
TRIL
102
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.25M 0.09%
172,307
– –
ILMN icon
103
Illumina
ILMN
$28.2B
$1.93M 0.07%
+11,308
New +$2.29M
VRTX icon
104
Vertex Pharmaceuticals
VRTX
$123B
$1.93M 0.07%
+18,500
New +$2.38M
LJPC
105
DELISTED
La Jolla Pharmaceutical Company
LJPC
$1.81M 0.07%
+65,000
New +$2.05M
VCYT icon
106
Veracyte
VCYT
$4.72B
$1.8M 0.07%
383,256
– –
ATEC icon
107
Alphatec Holdings
ATEC
$1.31B
$1.64M 0.06%
415,228
– –
PTN
108
Palatin Technologies
PTN
$16.2M
$1.62M 0.06%
1,600
– –
BIIB icon
109
Biogen
BIIB
$30.4B
$1.6M 0.06%
+5,500
New +$1.82M
KIN
110
DELISTED
Kindred Biosciences, Inc.
KIN
$1.45M 0.06%
279,204
– –
APYX icon
111
Apyx Medical
APYX
$180M
$1.34M 0.05%
688,229
– –
NVTA
112
DELISTED
Invitae Corporation
NVTA
$1.2M 0.05%
166,666
– –
KND
113
DELISTED
Kindred Healthcare
KND
$1.14M 0.04%
72,100
+1,986
+3% +$40.2K
THC icon
114
Tenet Healthcare
THC
$16.8B
$1.02M 0.04%
+27,602
New +$1.43M
CDNA icon
115
CareDx
CDNA
$2.05B
$955K 0.04%
229,000
– –
ESPR
116
DELISTED
Esperion Therapeutics
ESPR
$778K 0.03%
32,970
+12,070
+58% +$757K
HALO icon
117
Halozyme
HALO
$9.23B
$676K 0.03%
+50,349
New +$1.01M
CAH icon
118
Cardinal Health
CAH
$53.5B
$615K 0.02%
+8,000
New +$669K
SEM
119
DELISTED
Select Medical
SEM
$593K 0.02%
+102,080
New +$757K
ISEE
120
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$405K 0.02%
+10,000
New +$530K
BHC icon
121
Bausch Health
BHC
$1.8B
$281K 0.01%
+1,575
New +$367K
POZN
122
DELISTED
POZEN INC
POZN
$260K 0.01%
44,583
– –
ASXC
123
DELISTED
Asensus Surgical, Inc.
ASXC
$140K 0.01%
4,755
-17,912
-79% -$664K
AMPH icon
124
Amphastar Pharmaceuticals
AMPH
$871M
– –
-448,532
Closed -$7.88M
ASND icon
125
Ascendis Pharma A/S
ASND
$17.1B
– –
-20,859
Closed -$369K
2 3 4
5
6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2015 Portfolio in Review

As of Q3 2015, Deerfield Management held 151 positions worth $2.59B, down 14% from $3B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Deerfield Management withdrew a net $178M in Q3 2015, closing 17 positions and reducing 32 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 71% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Global Blood Therapeutics, Inc. worth $37.5M.

  • Deerfield Management's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 890,620 shares worth $37.5M.
  • Deerfield Management added most to AAC Holdings in Q3 2015, an estimated $37.8M increase.
  • Deerfield Management's biggest Q3 2015 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $132M.
  • Deerfield Management fully exited Spark Therapeutics, Inc. Common Stock in Q3 2015, selling an estimated $38M.
  • Deerfield Management's ten largest holdings make up 31% of its $2.59B portfolio in Q3 2015.
  • Deerfield Management opened 30 new positions and closed 17 in Q3 2015.
  • Deerfield Management's portfolio value fell 14% quarter-over-quarter to $2.59B.

Based on Deerfield Management's 13F filing for Q3 2015, filed 16 Nov 2015.